{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:19:38Z","timestamp":1790198378661,"version":"4.1.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tramadol and tilidine (in combination with naloxone) are used as weak opioid analgesics in Germany. Tramadol is not scheduled in the German Narcotic Drugs Act. Tilidine is scheduled, whereas Tilidine in fixed combinations with naloxone is exempt from some of the provisions of the Narcotic Drugs Act. Recent reports on misuse of both substances led to an evaluation of their potential for misuse, abuse, and dependency by the expert advisory committee established by the German Federal Government, resident at the Federal Institute for Drugs and Medical Devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A subcommittee formulated key questions and identified available data sources for each of these questions. Additional information was solicited where necessary, including a survey among a panel of pharmacists, a survey in an addiction clinic, analysis of prescription patterns, and information from the boards of pharmacists of the federal states and the Federal Bureau of Criminal Investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analgesic efficiency in the treatment of acute and chronic pain has been proven for both tramadol and tilidine\/naloxone. For tramadol, high evidence has been confirmed in systematic reviews, and tramadol is listed in national and international guidelines on acute and chronic pain management. Animal and human studies found a low potential for misuse, abuse, and dependency for both substances. Information from 2 tramadol safety databases allowed calculation of the incidence of abuse or dependency as 0.21 and 0.12 cases per million defined daily dosages (DDDs), with lower incidences in recent years. For tilidine\/naloxone, the incidence was calculated as 0.43 cases per million DDDs for oral solution and 0.18 for slow-release tablets. In an online survey among German pharmacies as well as in the reports from state pharmacy boards, fraud attempts were repeated more frequently with tilidine\/naloxone than with tramadol in the last 2\u00a0years. The Federal Bureau of Criminal Investigations reported prescription fraud only with tilidine\/naloxone and predominantly in the region of Berlin. Dependency on tramadol or tilidine\/naloxone is reported only rarely from addiction counseling centers. One third of the patients surveyed in an addiction clinic reported experiences with tramadol or tilidine\/naloxone, but mostly with duration of less than 4 weeks and with a medical prescription based on a reasonable indication. Also, occasional illegal use of opioid analgesics as a substitute of heroin was reported. An evaluation of pooled data from statutory health insurance companies found 2.5% of persons receiving at least 1 prescription of tramadol or the combination of tilidine and naloxone in 2009 (1.6% with tramadol and 1.0% with tilidine\/naloxone). High usage with more than 180 DDDs per year was found in 8.6% of patients treated with tramadol and 17.2% of patients with tilidine\/naloxone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, the subcommittee of the expert advisory committee found a low potential for misuse, abuse, and dependency for tramadol, and a low prevalence in clinical practice. Considerable less information is available for the combination of tilidine and naloxone. However, the cumulation of evidence indicated a higher risk of misuse, abuse, and dependency for tilidine\/naloxone solution, but not for slow-release tablets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2012.735216","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T10:04:03Z","timestamp":1353924243000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":75,"title":["Topical Review on the Abuse and Misuse Potential of Tramadol and Tilidine in Germany"],"prefix":"10.1177","volume":"34","author":[{"given":"Lukas","family":"Radbruch","sequence":"first","affiliation":[{"name":"Department of Palliative Medicine, University Hospital Bonn, Bonn, Germany"},{"name":"Center for Palliative Care, Malteser Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Glaeske","sequence":"additional","affiliation":[{"name":"Centre for Social Policy Research, University of Bremen, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Grond","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital Lippe-Detmold, Detmold, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"M\u00fcnchberg","sequence":"additional","affiliation":[{"name":"German Medicines Manufacturers\u2019 Association, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine and Addictive Disorders, LVR-Hospital Essen, Hospital of the University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Storz","sequence":"additional","affiliation":[{"name":"vfa\u2014Association of Research-Based Pharmaceutical Companies, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Tholen","sequence":"additional","affiliation":[{"name":"Centre for Social Policy Research, University of Bremen, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Zagermann-Muncke","sequence":"additional","affiliation":[{"name":"Drug Commission of German Pharmacists, Eschborn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Zieglg\u00e4nsberger","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Hoffmann-Menzel","sequence":"additional","affiliation":[{"name":"Center for Palliative Care, Malteser Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Greve","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cremer-Schaeffer","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"bibr1-08897077.2012.735216","author":"World Health Organization","year":"1996","journal-title":"Cancer Pain Relief: With a Guide to Opioid Availability"},{"key":"bibr2-08897077.2012.735216","unstructured":"World Health Organization. 1986. Cancer Pain Relief, Geneva: World Health Organization."},{"key":"bibr3-08897077.2012.735216","unstructured":"International Narcotic Control Board. 2011. Narcotic Drugs\u2014Estimated World Requirements for 2011, Statistics for 2009, New York: United Nations."},{"key":"bibr4-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0570-y"},{"key":"bibr5-08897077.2012.735216","first-page":"447","volume":"58","author":"Schulz M","year":"2003","journal-title":"Pharmazie"},{"key":"bibr6-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00004"},{"key":"bibr7-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.137273"},{"key":"bibr8-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-012-0737-z"},{"key":"bibr9-08897077.2012.735216","unstructured":"Bundesministerium f\u00fcr Justiz. 2011. Gesetz \u00fcber den Verkehr mit Bet\u00e4ubungsmitteln (Bet\u00e4ubungsmittelgesetz, BtMG)."},{"key":"bibr10-08897077.2012.735216","unstructured":"Bundesministerium f\u00fcr Justiz. 2011. Verordnung \u00fcber das Verschreiben, die Abgabe und den Nachweis des Verbleibs von Bet\u00e4ubungsmitteln (Bet\u00e4ubungsmittel-Verschreibungsverordnung, BtMVV)."},{"key":"bibr11-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03461.x"},{"key":"bibr12-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-13380-0"},{"key":"bibr13-08897077.2012.735216","unstructured":"IMS Health. 2010. DPM\u2014Der Pharmazeutische Markt Deutschland. Statistik \u00fcber Human- Arzneimittel-Eink\u00e4ufe \u00f6ffentlicher Apotheken, Frankfurt am Main: IMS Health."},{"key":"bibr14-08897077.2012.735216","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. 2010. ATC\/DDD Index 2011. Available at: http:\/\/www.whocc.no\/atc_ddd_index.\/ Accessed November 5, 2011"},{"key":"bibr15-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199615010-00002"},{"key":"bibr16-08897077.2012.735216","author":"Hollingshead J","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr17-08897077.2012.735216","unstructured":"Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Schmerztherapie. 2009. AWMF S3\u2014Leitlinie Akutschmerz. Available at: http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/041-001.html. Accessed November 5, 2011"},{"key":"bibr18-08897077.2012.735216","first-page":"3","author":"Arzneimittelkommission der Deutschen \u00c4rzteschaft","year":"2007","journal-title":"Arzneiverordnung in der Praxis"},{"key":"bibr19-08897077.2012.735216","unstructured":"Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM; APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. 2010. Acute Pain Management: Scientific Evidence 3rd ed., Melbourne, Australia: ANZCA & FPM. Available at: http:\/\/www.anzca.edu.au\/resources\/books-and-publications. Accessed November 5, 2011"},{"key":"bibr20-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-009-0839-9"},{"key":"bibr21-08897077.2012.735216","unstructured":"Bundes\u00e4rztekammer, Kassen\u00e4rztliche Bundesvereinigung, Arbeitsgemeinschaft Wissenschaftlich-Medizinischer Fachgesellschaften. 2010. Nationale VersorgungsLeitlinie Kreuzschmerz. Available at: http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/nvl-007.html. Accessed November 5, 2011"},{"key":"bibr22-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2008.00897.x"},{"key":"bibr23-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181131"},{"key":"bibr24-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1919-3"},{"key":"bibr25-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsycho.2006.01.010"},{"key":"bibr26-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(78)90010-8"},{"key":"bibr27-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(86)90059-1"},{"key":"bibr28-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(91)90081-9"},{"key":"bibr29-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.10.006"},{"key":"bibr30-08897077.2012.735216","first-page":"55","volume":"140","author":"Roider G","year":"2000","journal-title":"Deutsche Apotheker Zeitung."},{"key":"bibr31-08897077.2012.735216","unstructured":"Gr\u00fcnenthal. 2010. Scientific Evaluation of the Abuse Situation of Tramadol Containing Medicinal Products, Stolberg: Gr\u00fcnenthal."},{"key":"bibr32-08897077.2012.735216","unstructured":"Uppsala Monitoring Centre. 2011. Vigibase Services. Available at: http:\/\/www.umc-products.com\/DynPage.aspx?id=4910&mn=1107. Accessed November 6, 2011"},{"key":"bibr33-08897077.2012.735216","volume-title":"Bericht \u00fcber das gemeinschaftliche Drug-Monitoring Tilidin\/Naloxon-haltiger Arzneimittel f\u00fcr das Jahr 2010","author":"Lachmann N","year":"2011"},{"key":"bibr34-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P064"},{"key":"bibr35-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E577"},{"key":"bibr36-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2007.07.010"},{"key":"bibr37-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.9.599"},{"key":"bibr38-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1024\/0939-5911\/a000043"},{"key":"bibr39-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1078724"},{"key":"bibr40-08897077.2012.735216","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(85)90070-5"},{"key":"bibr41-08897077.2012.735216","first-page":"47","volume":"10","author":"Hellerstein D J","year":"2003","journal-title":"Primary Psychiatry."},{"key":"bibr42-08897077.2012.735216","unstructured":"World Health Organization. 2011. Ensuring Balance in National Policies on Controlled Substances\u2014Guidance for Availability and Accessibility of Controlled Medicines, Geneva: WHO Press."},{"key":"bibr43-08897077.2012.735216","first-page":"23","author":"World Health Organization","year":"2006","journal-title":"World Health Organ Tech Rep Ser 942."}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2012.735216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2012.735216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2012.735216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:43:35Z","timestamp":1777625015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2012.735216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1080\/08897077.2012.735216"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2012.735216","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}